Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1AS----[4] 53, 96, 215, 271
2Calcium[1] Calcium---[27] 6, 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 156, 214, 215, 222, 224, 235, 265, 274, 298, 299
3Calcium gluconate[2] Calcium,
Calcium gluconate		[1] D00935 --[3] 214, 215, 235
4Coenzyme Q10[1] Ubidecarenone[1] D01065 --[11] 2, 5, 6, 8, 10, 18, 46, 57, 113, 214, 215
5Cold Cadioplegia----[1] 215
6DEXMEDETOMIDINE[1] Dexmedetomidine[1] D00514 [3] ADRA2A,
ADRA2B,
ADRA2C 💬		[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬[14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
7Dexmedetomidine Hcl 100 Mcg/mL Inj[1] Dexmedetomidine[1] D00514 [3] ADRA2A,
ADRA2B,
ADRA2C 💬		[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬[1] 215
8Dobutamin[1] Dobutamine[1] D03879 [1] ADRB1 💬[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 215
9Dobutamine[1] Dobutamine[1] D03879 [1] ADRB1 💬[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[4] 57, 58, 86, 215
10Eplerenone[1] Eplerenone[1] D01115 [1] NR3C2 💬[1] Aldosterone-regulated sodium reabsorption 💬[4] 75, 113, 210, 215
11Fentanyl[1] Fentanyl[1] D00320 [1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[3] 46, 70, 215
12Fentanyl (High Dose)[1] Fentanyl[1] D00320 [1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 215
13Fentanyl (Low Dose)[1] Fentanyl[1] D00320 [1] OPRM1 💬[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬[1] 215
14Fentanyl (Low Dose) + Dexmedetomidine[2] Dexmedetomidine,
Fentanyl		[2] D00320 ,
D00514 		[4] ADRA2A,
ADRA2B,
ADRA2C,
OPRM1 💬		[4] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬[1] 215
15Fluorescite----[1] 215
16HTK cardioplegia----[1] 215
17KETAMINE[1] Ketamine[1] D08098 [5] GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		[20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬[6] 6, 13, 70, 113, 156, 215
18Losartan[1] Losartan[1] D08146 [1] AGTR1 💬[16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[17] 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
19LOSARTAN POTASSIUM[2] Losartan,
Potassium		[2] D08146 ,
D08403 		[1] AGTR1 💬[16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[5] 36, 98, 167, 179, 215
20Potassium[1] Potassium[1] D08403 --[13] 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235
21Recombinant human brain natriuretic peptide (rhBNP)----[1] 215
22Sodium citrate[1] Sodium citrate[2] D01781 ,
D05855 		--[4] 67, 214, 215, 235
23SULFUR HEXAFLUORIDE[1] Sulfur hexafluoride[1] D05962 --[2] 96, 215
24Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON][1] Sulfur hexafluoride[1] D05962 --[1] 215
25Tranexamic acid[1] Tranexamic acid[1] D01136 [1] PLG 💬[4] Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection 💬[7] 46, 70, 215, 227, 274, 288, 299